Riskpilot← Back to searchSign inGet full accessAstraZeneca Biotech AB
ABActiveOrg 5567305312Activities of holding companies · NACE 6421Est. 20070 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
99.8%
Financial strength
Net profit 2024
SEK 7,4B
+284% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK 7,4B | +284% |
| Total assets | SEK 57B | +15% |
| Equity | SEK 56,9B | +15% |
| Employees | 0 | — |
Legal name
AstraZeneca Biotech AB
Org number
5567305312
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
24 maj 2007
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten externa firmatecknarna
Company purpose
Föremålet för bolagets verksamhet skall omfatta forskning, utveckling, tillverkning, köp och försäljning av tjänster och produkter av biotekniskoch/eller medicinsk karaktär samt annan därmed förenlig rörelse samt att äga och förvalta fast och lös egendom, däribland aktier och andelar i andra företag.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | — | — | — | — | — | — | — | — | — | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net financials | −65 583 | −142 977 | −26 773 | 13 221 | 7 217 470 | — | — | −61 061 000 | −7 878 345 | −12 695 |
| Profit before tax | 5 247 291 | 5 060 718 | 3 673 226 | 5 213 221 | 8 717 470 | 2 375 910 | 1 544 469 | −58 561 000 | −3 878 345 | 7 487 306 |
| Tax | −0 | −0 | −0 | −0 | 89 582 | −89 582 | −0 | −0 | −141 394 | −110 865 |
| Net profit | 5 247 291 | 5 060 718 | 3 673 226 | 5 213 221 | 8 807 052 | 2 286 328 | 1 544 469 | −58 561 000 | −4 019 739 | 7 376 441 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 107 372 129 | 107 221 528 | 107 221 528 | 107 221 528 | 107 311 111 | 109 721 528 | 112 121 528 | 53 560 528 | 49 682 183 | 57 028 095 |
| Equity | 107 371 989 | 107 221 528 | 107 221 528 | 107 221 528 | 107 311 111 | 109 721 528 | 112 121 528 | 53 560 528 | 49 540 789 | 56 917 230 |
| Long-term debt | 140 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 141 394 | 110 865 |
| Total debt | 140 | — | — | — | — | — | — | — | 141 394 | 110 865 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20152024
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20152024
Return on equity
13.0%
This company
18.4%
Market median
+29% vs market
20152024
Net profit margin
737644100000.0%
This company
8.1%
Market median
+9106717283851% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AP External Signatory | External Signatory | 2025 | — | — |
KC External Signatory | External Signatory | 2020 | — | — |
SI Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Astrazeneca AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Astrazeneca AB
AstraZeneca Biotech AB (this company)Medimmune Ventures IncMedimmune LlcMEDIMMUNE LLCMEDIMMUNE VENTURES INCBoard members of AstraZeneca Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Pia Seo-Hwa Ejeholt | External Signatory | 0 companies |
| Karin Christina Eriksson | External Signatory | 0 companies |
| Sebastian Ionescu | Chief Auditor | 0 companies |
| Derek John Seaborn | Board of Directors | 0 companies |
| James Stewart Fox | Deputy Board Member | 0 companies |
| Besiana Alite | Deputy Board Member | 0 companies |
| Yvonne Louise Bertlin | Chairman | 0 companies |
| James Stewart Fox | Deputy Board Member | 0 companies |
| Lars-Johan Cederbrant | Board of Directors | 0 companies |
| Per Johan Engstam | Deputy Board Member | 0 companies |